News, Videos, and More from the City of Racine, the State of Wisconsin, the USA, & the World
Friday, May 22, 2020
Pathway Rx Advances Research that Shows Potential for Medical Cannabis to Treat COVID-19
Data collected from previous studies conducted in collaboration with Swysh and commercial partner Sundial Growers reveals that some medical cannabis cultivars can help reduce the severity and complications of COVID-19 disease
LETHBRIDGE, AB, May 5, 2020 /CNW/ - Pathway RX Inc. ("Pathway Rx"), a research company dedicated to developing custom cannabis therapies to treat specific diseases and Swysh Inc. ("Swysh"), a cannabinoid oral health product developer, today announced that they intend to further advance their research to evaluate the potential for medical cannabis to treat COVID-19 and its possible complications. These efforts will include the publication of more research papers and the initiation of clinical trials to validate the safety and efficacy of medical cannabis to treat COVID-19.
Results from a study by Pathway Rx were recently shared publicly and the research paper was submitted to a scientific journal for peer-review. The study's data suggests that a limited sample of high CBD Cannabis sativa extracts modulate ACE2 gene expression and ACE2 protein levels in gateway tissues of the COVID-19 causing virus and also have the potential to inhibit its entry into cells, curtail disease spread and reduce mortality. The study was conducted using artificial human 3D models of oral, airway, and intestinal tissues. A second research study that examines the use of cannabis extracts for taming the cytokine storm will be published soon.
"Angiotensin-converting enzyme 2 (ACE2) has been generally accepted by the scientific community as a receptor required for the entry of SARS-CoV-2 into human cells," said Dr. Igor Kovalchuk, CEO of Pathway Rx and holder of a Health Canada License for Cannabis Research. He added that, "Our initial findings warrant further investigation but it's possible that medical cannabis products could become a safe adjunct therapy for the treatment of COVID-19."
Among the 1,000 Cannabis sativa varieties that have been screened by Pathway Rx, only a small number have expressed medicinal properties. The most promising of these varieties are licensed to Pathway Rx's commercial partner Sundial Growers Inc. (Nasdaq: SNDL) and are currently in production at its facility in Olds, Alberta.
Pathway Rx aims to seek funding from many sources to support its research goals including the recently announced $1.1 billion from the Canadian Government to support scientific initiatives to address COVID-19. "The Government of Canada's latest investment to support the health of Canadians creates a significant opportunity for Pathway Rx to advance our research and accelerate the development of custom therapies and products to help combat COVID-19," said Dr. Kovalchuk.
PLEASE BE SURE TO READ OUR DISCLAIMER AT THE BOTTOM OF THE PAGE
This website exists for entertainment purposes only. The reader is responsible for discerning the validity of information posted here, be it fictional or based on real events or people. The content of posts on this site, including but not limited to links to other web sites, are the expressed opinion of the original poster and are in no way representative of or endorsed by the owners or administration of this website. The posts on this website are the opinion of the specific author and are not statements of advice, opinion, or factual information on behalf of the owner or administration of JT Irregulars. This site may contain adult content and if you feel you might be offended by such content, you should log off immediately.
Not all posts on this website are intended as truthful or factual assertion by their authors. Some users of this website are participating in internet role playing, with or without the use of an avatar. NO post on this website should be considered factual information on face value alone. Users are encouraged to USE DISCERNMENT and do their own follow up research while reading and posting on this website. JT Irregulars reserves the right to make changes to, corrections and/or remove entirely at any time posts made on this website without notice. In addition, JT Irregulars disclaims any and all liability for damages incurred directly or indirectly as a result of a post on this website.
This site is provided "as is" without warranty of any kind, either expressed or implied. You should not assume that this site is error-free or that it will be suitable for the particular purpose which you have in mind when using it. In no event shall JT Irregulars be liable for any special, incidental, indirect or consequential damages of any kind, or any damages whatsoever, including, without limitation, those resulting from loss of use, data or profits, whether or not advised of the possibility of damage, and on any theory of liability, arising out of or in connection with the use or performance of this site or other documents which are referenced by or linked to this site.
Some events depicted in certain posting and threads on this website may be fictitious and any similarity to any person living or dead is merely coincidental. Some other articles may be based on actual events but which in certain cases incidents, characters and timelines have been changed for dramatic purposes. Certain characters may be composites, or entirely fictitious. We do not discriminate against the mentally ill!
Administrators may close an account, remove any post or comment and cancel author accounts as they, alone, deem necessary. You may contact the administration at email@example.com to report inappropriate use or to ask for the removal of specific material. The administration retains the final decision of what content constitutes appropriate use and what content is displayed.
Fair Use Notice: This site may contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. Users may make such material available in an effort to advance awareness and understanding of issues relating to civil rights, economics, individual rights, international affairs, liberty, science & technology, etc. We believe this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C.Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.